GPRC5D Market Summary

Key Highlights

• The GPRC5D market is expected to grow significantly by 2036.
• GPRC5D is highly expressed on malignant plasma cells in a large proportion of patients with multiple myeloma.
• Currently, TALVEY (talquetamab-tgvs), approved in August 2023, is the first and the only approved GPRC5D-directed therapy in the market.
• In the US, there were around 33,700 incident cases of multiple myeloma in 2024, which was the highest among seven major markets.
• Leading GPRC5D-directed therapies companies, such as Bristol Myers Squibb (Juno Therapeutics), AstraZeneca, Oricell, CARsgen Therapeutics, Sanofi, Jiangsu Simcere Pharmaceutical, AbbVie, and others, are developing novel GPRC5D-directed therapies that can be available in the GPRC5D-directed therapies market in the coming years.
• Some of the key GPRC5D-directed therapies in the pipeline include Arlocabtagene autoleucel (BMS-986393), AZD0305, OriCAR-017, CT071, SAR446523, SIM0500, and others.

DelveInsight’s “GPRC5D Market Size, Target Population, Competitive Landscape & Market Forecast - 2036” report delivers an in-depth understanding of GPRC5D, addressable patient pool, competitive landscape, and future market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan.

The GPRC5D market report provides insights around existing treatment practices in patients with GPRC5D, approved (if any) and emerging GPRC5D, market share of individual therapies, patient pool eligible for treatment with GPRC5D, along with current and forecasted 7MM GPRC5D market size from 2022-2036 by therapies and by indication. The report also covers current unmet needs and challenges while incorporating new classes in treatment paradigm, variations in accessibility and acceptability of new GPRC5D in different geographies, along with insights on GPRC5D pricing reimbursements to curate the best opportunities and assess the market’s potential.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain), and the UK
• Japan

Study Period: 2022–2036

GPRC5D Overview

GPRC5D (G protein-coupled receptor class C group 5 member D) is a cell-surface receptor that belongs to the class C family of G protein-coupled receptors (GPCRs). It is expressed predominantly in plasma cells, including malignant plasma cells in multiple myeloma, while showing limited expression across most normal tissues. This restricted expression pattern has made GPRC5D an attractive therapeutic target for multiple myeloma. GPRC5D-directed therapies are designed to recognize and bind the receptor on myeloma cells, enabling targeted elimination through mechanisms such as T-cell activation or antibody-dependent cellular cytotoxicity. Several therapeutic approaches, including bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapies, are being investigated to exploit GPRC5D as an alternative or complementary target to established multiple myeloma antigens such as BCMA.

GPRC5D in Clinical Practice

This section will give in depth information about the existing local and systemic options in the current treatment paradigm of all the potential indications, in which most of the pharmaceutical companies are actively evaluating their inhibitors. Potential of the emerging GPRC5D in changing the current clinical practice guidelines is crucial to analyze especially when it comes to real world scenario.

It will also include the relevance and importance of incorporation of biomarker testing at varying stages of the disease. It is also important to understand that implementing such tests in routine clinical practice is not uniform in different countries due to issues such as cost, accessibility, reimbursement and non-recommendation in guidelines.

GPRC5D Drug Chapters

The drug chapter segment of the GPRC5D report encloses a detailed analysis of marketed therapies and late-stage (Phase III and Phase II) therapies. It also helps understand the GPRC5D clinical trial details, pharmacological action, agreements and collaborations related to GPRC5D, their approval timelines, patent details, advantages and disadvantages, latest news and press releases.

GPRC5D Marketed Drugs

TALVEY: Johnson & Johnson

TALVEY is a novel, first-in-class bispecific T-cell engager that simultaneously binds to the CD3 receptor on T cells and GPRC5D, which is present on multiple myeloma cells, non-cancerous plasma cells, and certain healthy epithelial tissues, particularly in the skin and tongue. It is administered subcutaneously on a weekly or biweekly basis following an initial step-up dosing phase, giving physicians the flexibility to tailor dosing schedules to individual patient needs.

GPRC5D Emerging Drugs

OriCAR-017: Oricell

OriCAR-017 is an innovative CAR T cell therapy developed to target GPRC5D, aimed at treating relapsed or refractory multiple myeloma. Developed using Oricell Therapeutics’ advanced proprietary technology, OriCAR-017 demonstrates unique advantages in terms of binding strength, cell persistence, tumor-fighting capability, and safety. It received Investigational New Drug (IND) approval from the U.S. FDA in January 2024, following earlier approval by China’s NMPA in 2023.

Arlocabtagene autoleucel: Bristol-Myers Squibb

BMS-986393 is an autologous CAR T cell therapy also directed at GPRC5D. Currently under evaluation in the Phase II QUINTESSENTIAL trial for relapsed/refractory multiple myeloma, the therapy is expected to yield key data in 2026. At the ASH 2023 conference, updated results from its Phase I trial highlighted durable responses, manageable safety, and clinical activity in patients regardless of prior BCMA-targeted treatment exposure.

Note: Detailed list will be provided in the final report.

Recent Developments in the GPRC5D Market

• In September 2026, BMS reported positive Phase 2 QUINTESSENTIAL results for its GPRC5D-directed CAR-T therapy in heavily pretreated relapsed/refractory multiple myeloma. The study met its primary overall-response-rate endpoint and key secondary complete-response endpoints, supporting arlo-cel as a potential first-in-class GPRC5D-directed CAR-T therapy.
• In July 2026, Updated clinical experience with talquetamab highlighted its potential sequencing role in multiple myeloma. Data from MonumenTAL-1 indicated a 78% overall response rate among patients subsequently receiving BCMA CAR-T therapy, suggesting that prior GPRC5D-directed treatment may not substantially compromise subsequent BCMA CAR-T efficacy.
• In June 2026, MonumenTAL-3 data presented at EHA 2026 reinforced efforts to move GPRC5D-directed therapy earlier in the multiple-myeloma treatment pathway, expanding evaluation beyond heavily pretreated disease.

Drug Class Insights

The Drug Class Insights section will provide comprehensive information on GPRC5D as a class. This will include a broad overview of the class and its role in treating specific conditions. Insights may cover the historical clinical development of GPRC5D, their mechanism of action, their subtypes and future commercial prospects. Additionally, the section will provide detailed information about current trends, challenges, and future prospects for this class of drugs.

GPRC5D Market Outlook

This section will include details on changing GPRC5D market dynamics post initiation of clinical development activities of the inhibitor. It will also provide a detailed summary and comparison of all the therapies being developed by leading players in this space. This section will highlight the advantages of one therapy over the other after assessment based on parameters such as data availability in the form of safety and efficacy, number of patients enrolled in each trial, and trial’s inclusion criteria. There will be a Key focus on the importance of development and need for the commercial success of these targeted therapies to achieve treatment goals that physicians and patients are looking for. It will also sum up all the early stage players active in this space.

GPRC5D Drugs Uptake

This section focuses on the uptake rate of potential GPRC5D already launched and expected to be launched in the market during 2022–2036, which depends on the competitive landscape, safety, efficacy data, and order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake.

GPRC5D Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III and Phase II stages. It also analyzes key players involved in developing targeted therapeutics.

GPRC5D Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for GPRC5D.

KOL Views

To keep up with current and future market trends, we incorporate Key physicians, Therapy Area Researcher’s, and other Industry Experts’ opinions working in the domain through primary research to fill in the data gaps and validate our secondary research. 25+ Key Opinion Leaders (KOLs) were contacted for insights on GPRC5D’ incorporation in the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, drug uptake, along with challenges related to accessibility.

Qualitative Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Analyst views. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the analyst’s discretion and assessment of the cost analysis and existing and evolving treatment landscape.

Market Access and Reimbursement

This section will include insights around the standard HTA pricing, recent reformations in 2024 and modifications in reimbursement process in the 7MM. For example, In the United States, a multi payer model exists when it comes to drug pricing regime, which is currently undergoing significant changes, with recent federal legislation, such as the Prescription Drug Pricing Reform provisions of the Inflation Reduction Act, significantly altering the pricing regime under certain federal programs. Whereas in Germany, the market access differs from the systems followed in many other countries as no pricing and reimbursement approval is required during launch of a new therapy.

Moreover, this section will also provide details on reimbursement of approved therapy, if any.

Scope of the Report

• The report covers a segment of key events, an executive summary, target patient pool, epidemiology and market forecasts, information around patient journey and varying biomarker testing rates
• Additionally, an all-inclusive account of the current and emerging therapies drug chapters, insights on GPRC5D addressable patient pool
• A detailed review of the GPRC5D market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, and treatment preferences that help in shaping and driving the 7MM GPRC5D market.
• Market Size of Inhibitors by therapies and indication will be provided

GPRC5D Report Key Strengths

• 11 Years GPRC5D Market Forecast
• The 7MM Coverage
• GPRC5D Competitive Landscape of current and emerging therapies
• GPRC5D Total Addressable patient population
• Drugs Uptake and Key Market Forecast Assumptions
• Approved and Emerging therapy Profiles
• Physician’s perspectives/KOL opinions
• Biomarker testing and Patient journey
• Qualitative Analysis (SWOT and Analyst Views)
• GPRC5D Market Size by therapy and indication
• Existing and Future Market Opportunity
• Unmet Needs

FAQs

• What was the GPRC5D total market size, the market size by therapies, market share (%) distribution in 2022, and what would it look like by 2036? What are the contributing factors for GPRC5D market growth?
• Which drug is going to be the largest contributor by 2036?
• What is the market access and reimbursement scenario of GPRC5D?
• What are the pricing variations among different geographies?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?

Reasons to Buy

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the GPRC5D Market.
• Understand the existing GPRC5D market opportunities and future trends in varying geographies
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders’ perspectives around the accessibility and acceptability of emerging treatment options along with unmet need of current therapies
• Details on report methodology, top indications covered, market assumptions, patient journey and KOLs to strengthen the pharmaceutical companies’ development and launch strategy.